Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Characterization of human aging and Parkinson’s disease pre-frontal cortex by multi-omics: a glycomics, proteomics study.

ABSTRACT: This study identifies the age and PD related changes in glycans (HS and CS disaccharides) and proteomics in human aging and Parkinson’s disease. We analyzed the prefrontal cortex for changes in HS, CS and proteomic signatures in young versus aged as well as aged and PD in two cohorts. These studies provide insight into age- and PD changes in glycans and proteomics. We assess changes with PD and observe for pathways that may correlate with transcriptomics. We also observe in aging related proteomic changes and transcriptomics for changes in common with PD that may describe risk of disease.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Brain

DISEASE(S): Parkinson's Disease

SUBMITTER: Rekha Raghunathan

LAB HEAD: Joseph Zaia

PROVIDER: PXD018736 | Pride | 2020-07-16

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20170913_RR_PD1.mgf	Mgf
	20170913_RR_PD1.mzML	Mzml
	20170913_RR_PD1.raw	Raw
	20170913_RR_PD2.mgf	Mgf
	20170913_RR_PD2.mzML	Mzml

Items per page:

1 - 5 of 604

Similar Datasets

Glycomic and Proteomic changes in aging brain nigrostriatal pathway

Project description:This study identifies the age related changes in glycan receptors of heparan sulfate (HS) proteoglycan (receptor for rAAV2), and/or N-glycans with terminal galactose (receptor for rAAV9) and proteomics for receptors and co-receptors of adeno-associated virus in the nigro-striatal region of the brain. We analyzed the striatum and substantia nigra for changes in HS, N-glycans and proteomic signatures in young versus aged rat brain nigro-striatum from histological sections. These studies provide insight into age- and brain region-specific changes in glycan receptors and proteomics that will inform design of improved viral vectors for Parkinson’s disease gene therapy.

2018-06-27 | PXD008990 | Pride

Targeting Glycomes Sensitizes Ovarian Tumors to Immune Checkpoint Blockade

Project description:Aberrant glycosylation is a crucial strategy employed by cancer cells to evade cellular immunity. However, homologous recombination (HR) status-dependent glycosylation has never been explored therapeutically. Here, we show that the inhibition of branched N-glycans sensitizes HR-proficient, but not HR-deficient, epithelial ovarian cancers (EOCs) to immune checkpoint blockade (ICB). In contrast to fucosylation whose inhibition sensitizes EOCs to anti-PD-L1 immunotherapy regardless of HR-status, we observe a unique enrichment of branched N-glycans on HR-proficient compared to HR-deficient EOCs. Mechanistically, BRCA1/2 transcriptionally promotes the expression of MGAT5, the enzyme responsible for catalyzing branched N-glycans. The branched N-glycans on HR-proficient tumors augment their resistance to anti-PD-L1 by enhancing its binding with PD-1 on CD8_ T cells. In orthotopic syngeneic EOC mouse models, inhibiting branched N-glycans, using 2-Deoxy-D-glucose, sensitizes HR-proficient, but not HR-deficient EOCs, to anti-PD-L1. These findings indicate branched N-glycans as promising therapeutic targets whose inhibition sensitizes HR-proficient EOCs to ICB by overcoming immune evasion

2024-03-11 | GSE244012 | GEO

Targeting Glycomes Sensitizes Ovarian Tumors to Immune Checkpoint Blockade II

2024-09-29 | GSE244367 | GEO

Integrative glycomic and proteomic analysis of mouse striatum and lateral hypothalamus following cocaine and methamphetamine treatment

Project description:Drug abuse is a major concern with few therapeutic options. Heparan sulfate (HS) and chondroitin sulfate (CS) interact with a plethora of growth factors and their receptors, and have profound effects on cellular signaling. Thus, targeting these dynamic interactions represents a novel therapeutic modality. Our previous studies have indicated increased HS proteoglycan syndecan-3 and identified HS as a resilience factor for cocaine abuse. Here, we utilized mass spectrometry-based glycomics and proteomics to understand the effects of cocaine (C) and methamphetamine (M) on HS, CS, and proteins from two brain regions: lateral hypothalamus (LH) and striatum (ST) from mice. We observed significant differences in HS and CS total abundances and percent sulfate contents and reduction in CS 4-O-sulfation, and increase in CS 6-O-sulfation for drug-treated (C and M) vs. saline samples. The proteomics data revealed a number of aberrant proteins in drug-treated vs. saline samples, including MYPR, KCC2A, SYN2, TENR, CALX, ANXA7, HDGF, NCAN, and CSPG5, and oxidative phosphorylation among the top perturbed pathway. Taken together, our study shows for the first time the novel relationship of HS, CS, and associated proteins with the drug abuse, and shed light on, the underlying neurobiological mechanism of drug dependence and novel therapeutic options.

2024-09-04 | PXD038576 | Pride

GNPS - Advancing a high throughput glycotope-centric glycomics workflow based on nanoLC-MS2-product dependent-MS3 analysis of permethylated glycans

Project description:1. NanoLC-MS2-pd-MS3 dataset on permethylated sulfated AGS O-Glycans 2. NanoLC-MS2-pd-MS3 dataset for the permethylated N-glycans of mouse brain striatum

2017-06-19 | MSV000081172 | GNPS

Proteoglycan profiling of human, rat and mouse insulin-secreting cells

Project description:Proteoglycans (PGs) are proteins with glycosaminoglycan (GAG) chains, such as chondroitin sulfate (CS) or heparan sulfate (HS), attached to serine residues. We have earlier shown that prohormones can carry CS, thus, constituting a novel class of PGs. The mapping of GAG modifications of proteins in endocrine cells may thus assist us in delineating possible roles of PGs in endocrine cellular physiology. With this aim, we applied a glycoproteomic approach to identify PGs, their GAG chains and their attachment sites in insulin-secreting cells. Glycopeptides carrying GAG chains were enriched from human pancreatic islets, rat (INS-1 832/13) and mouse (MIN6, NIT-1) insulinoma cell lines by ion exchange chromatography, depolymerized with GAG lyases, and analyzed by nanoflow liquid chromatography-tandem mass spectrometry (nLC-MS/MS). We identified CS modifications of chromogranin-A, islet amyloid polypeptide, secretogranin 1 and secretogranin 2, immunoglobulin superfamily member 10, and protein AMBP. Additionally, we identified two HS-modified prohormones (chromogranin-A and secretogranin-1), which was surprising, as prohormones are not typically regarded as HSPGs. For chromogranin-A, the glycosylation site carried either CS or HS, making it a so-called hybrid site. Additional HS sites were found on syndecan-1, syndecan-4, nerurexin-2, protein NDNF, and testican-1. These results demonstrate that several prohormones, and other constituents of the insulin-secreting cells are PGs. Cell-targeted mapping of the GAG glycoproteome forms an important basis for better understanding of endocrine cellular physiology, and the novel CS and HS sites presented here provide important knowledge for future studies.

2022-02-16 | PXD024230 | Pride

Transcriptional changes in response to oxidative stress in combination with temperature extremes in rice

Project description:Genome wide expression profiles of 10-day-old seedlings in response to prior exposure with OS followed by heat stress or cold stress as well simultaneous exposure to OS along with HS/CS was done to study the transcriptional changes in response to combination of stresses.

2012-12-26 | GSE32704 | GEO

Profiling of Serum N-glycosylation in Non-small-cell Lung Cancer

Project description:Aberrant serum N-glycan profiles have been observed in multiple cancers including non-small-cell lung cancer (NSCLC), yet the potential of N-glycans in the early diagnosis of NSCLC remains to be determined. Here, serum N-glycan profiles of 275 NSCLC patients and 309 healthy controls were characterized by MALDI-TOF-MS. The levels of serum N-glycans and N-glycosylation patterns were compared between NSCLC and control groups. In addition, a panel of N-glycan biomarkers for NSCLC diagnosis was established and validated using machine learning algorithms. As a result, a total of 54 N-glycan structures were identified in human serum. Compared with healthy controls, 29 serum N-glycans were up- or down-regulated in NSCLC patients. N-glycan abundance in different histological types or clinical stages of NSCLC presented differentiated changes. Furthermore, an optimal biomarker panel of 8 N-glycans was constructed based on logistic regression, with an AUC of 0.86 in the validation set. Notably, this model also showed a desirable capacity in distinguishing early-stage patients from healthy controls (AUC = 0.88). In conclusion, our work highlights the abnormal N-glycan profiles in NSCLC and provides supports for the promising potential of N-glycan panels in clinical NSCLC detection.

2023-11-23 | PXD040883 | Pride

NanoLC-MS2-pd-MS3 dataset

Project description:1. NanoLC-MS2-pd-MS3 dataset on permethylated sulfated AGS O-Glycans. 2. NanoLC-MS2-pd-MS3 dataset for the permethylated N-glycans of mouse brain striatum.

2017-06-19 | MSV000081173 | MassIVE

Advancing a high throughput glycotope-centric glycomics workflow based on nanoLC-MS2-product dependent-MS3 analysis of permethylated glycans

Project description:1. NanoLC-MS2-pd-MS3 dataset on permethylated sulfated AGS O-Glycans 2. NanoLC-MS2-pd-MS3 dataset for the permethylated N-glycans of mouse brain striatum

2017-06-22 | MSV000081184 | MassIVE

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data